"Competitive Analysis of Executive Summary Alpha and Beta Emitters Based Radiopharmaceuticals Market Size and Share CAGR Value The global alpha and beta emitters based radiopharmaceuticals market size was valued at USD 801.45 million in 2024 and is expected to reach USD 1,769.20 million by 2032, at a CAGR of 10.4% during the forecast period A competition...

"Executive Summary Cancer Biomarkers Market Value, Size, Share and Projections CAGR Value Data Bridge Market Research analyses that the cancer biomarkers market, which was USD 13.24 billion in 2022, would rocket up to USD 36.74 billion by 2030 and is expected to undergo a CAGR of 13.6% during the forecast period from 2023 to 2030. The large scale Cancer Biomarkers Market report has...

ENHERTU (fam-trastuzumab deruxtecan) represents a paradigmatic shift in oncological therapeutics, fundamentally altering treatment landscapes for HER2-positive cancers worldwide. This cutting-edge antibody-drug conjugate, born from collaborative innovation between Daiichi Sankyo and AstraZeneca, has achieved unprecedented regulatory success with approvals encompassing breast cancer, gastric...

"Future of Executive Summary Gastroesophageal Junction Adenocarcinoma Therapeutics Market: Size and Share Dynamics During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 17.56%, primarily driven by the rising prevalence and treatments advancements Businesses can attain detailed insights with the large scale Gastroesophageal Junction Adenocarcinoma...

The global Intensity Modulated Radiotherapy (IMRT) market has emerged as one of the most vital segments of the cancer treatment landscape, providing oncologists with advanced tools to deliver precise radiation therapy. According to Kings Research, the IMRT market is projected to witness significant growth from 2024 to 2032, driven by rising cancer prevalence, expanding...

The global intensity modulated radiotherapy market size was valued at USD 2.47 billion in 2024 and is projected to grow from USD 2.59 billion in 2025 to USD 3.72 billion by 2032, exhibiting a CAGR of 5.35% during the forecast period. This growth is attributed to the rising adoption of IMRT across leading oncology centers and hospitals focused on precision cancer...

The Japan Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market is poised for significant growth, with its size projected to rise from USD 78.61 million in 2024 to USD 155.79 million by 2034, reflecting a compound annual growth rate (CAGR) of 7.10% over the forecast period. This market expansion is largely driven by increased awareness, advancements...

Before 2022, OPDIVO, developed through collaborative efforts between Ono Pharmaceutical and Bristol Myers Squibb, encountered formidable market challenges within Japan's increasingly competitive oncology landscape. The therapeutic agent experienced significant market decline as KEYTRUDA vs OPDIVO competition reached critical intensity, with medical professionals demonstrating growing preference...

The global peptide-based cancer therapeutics market is undergoing a period of rapid advancement, driven by the urgent need for effective, targeted cancer treatments and innovations in peptide drug design and delivery. According to recent industry analysis, the market was valued at USD 8.58 billion in 2019 and is projected to grow at a CAGR of 9.1%,...